Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis

Acta Tropica

Volumn 94, Issue 1, 2005, Pages 41-47

  Gupta, Suman ^a   Ramesh, ^a   Sharma, S C ^a   Srivastava, V M L ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Combination therapy; Hamster; Leishmania donovani; Miltefosine; Picroliv; Visceral leishmaniasis

Indexed keywords

ANTILEISHMANIAL AGENT; IMMUNOMODULATING AGENT; KUTKIN; MILTEFOSINE;

LEISHMANIASIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HAMSTER; LEISHMANIA DONOVANI; MALE; NONHUMAN; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

CRICETINAE; LEISHMANIA DONOVANI; MESOCRICETUS AURATUS; NASO HEXACANTHUS;

EID: 15944401368     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2004.11.009     Document Type: Article

References (25)

1. J. Alvar, B. Guitierrez-solar, I. Pachon, E. Calbacho, M. Ramirez, R. Valles, J. Guillen, C. Conavate, and C. Amela AIDS and L. infantum: new approaches for a new epidemiological problem Clin. Parasitol. 14 1996 541
2. R. Badaro, C. Nascimento, J.S. Carvalho, F. Badaro, D. Russo, J.L. Ho, G. Reed, W.D. Johnson Jr., and T.C. Jones Recombinant human granolocyte macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis J. Infect. Dis. 170 1994 413 418
3. J. Berenguer, S. Moreno, E. Cercenado, J.C.L.B. Dequiros, A.C. De La Fuente, and E. Bouza Visceral leishmaniasis in patients infected with human immunodeficiency virus Ann. Trop. Med. Parasitol. 111 1989 129 132
4. E. Beveridge Chemotherapy of leishmaniasis R.J. Schnitzer F. Hawking Experimental Chemotherapy vol. 1 1963 Academic Press New York, London 257 280
5. S. Bhatnagar, P.Y. Guru, J.C. Katiyar, R. Srivastava, A. Mukherjee, M.S. Akhtar, M. Seth, and A.P. Bhaduri Exploration of antileishmanial activity in heterocycles: results of their in vivo and in vitro bioevaluations Indian J. Med. Res. 89 1989 439
6. A. Bryceson A policy for leishmaniasis with respect to the prevention and control of drug resistance Trop. Med. Int. Health 6 2001 928 934
7. R. Chander, N.K. Kapoor, and B.N. Dhawan Picroliv affects γ-glutamyl cycle in liver and brain of Mastomys natalensis infection with Plasmodium berghei Indian J. Exp. Biol. 32 1994 324 327
8. Y. Dwivedi, R. Rastogi, S.K. Sharma, N.K. Garg, and B.N. Dhawan Picroliv afford protection against thioacetamide induced hepatic damage in rats Plant Med. 57 1991 25 28
9. Y. Dwivedi, R. Rastogi, N.K. Garg, and B.N. Dhawan Picroliv and its components kutkoside and Picroside I protect liver against galactosamine induced damage in rats Pharmacol. Toxicol. 71 1992 383 387
10. N.K. Ganguly Oral miltelfosine may revolutionize treatment of visceral leishmaniasis TDR News No. 68 June issue 2002 2
11. S. Gupta, S. Tiwari, A.K. Bagchi, and J.C. Katiyar A rising trend in kala-azar in Varanasi district, Uttar Pradesh. India: a recent survey using direct agglutination test Curr. Sci. 73 1997 456 459
12. T.K. Jha, P. Olliaro, C.P. Thakur, T.P. Kanyok, B.L. Singhania, I.J. Singh, N.K.P. Singh, S. Akhonry, and S. Jha Randomized controlled trial of aminosidine (Paramomycin) V. Sodium stibogluconate for treating visceral leishmaniasis in north Bihar, India Br. Med. J. ii 1998 1200
13. R. Kumar, P. Kumar, R.K. Chaudhari, K. Pai, C.P. Mishra, K. Kumar, H.P. Pandey, V.P. Singh, and S. Sundar Kala-azar epidemic in Varanasi district, India Bull. WHO 77 1999 371
14. H.W. Murray, J.D. Berman, and D.C. Wright Immunochemotherapy for Leishmania donovani infection: γ-interferon plus pentavalent antimony J. Infec. Dis. 157 1988 973 978
15. A. Puri, R.P. Saxena, Sumati, P.Y. Guru, D.K. Kulshreshtha, K.C. Saxena, and B.N. Dhawan Immunostimulant activity of picroliv, the irridoid glycoside fraction of Picrorhiza kurroa and its protective action against Leishmania donovani infections in hamsters Plant Med. 58 1992 528 532
16. R. Rastogi, S. Saksena, N.K. Garg, N.K. Kapoor, D.P. Agarwal, and B.N. Dhawan Picroliv protects against alcohol induced chronic hepatotoxicity in rats Plant Med. 62 1996 283 285
17. A.C. Smith, V. Yardley, J. Rhodes, and S.L. Croft Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis Antimicrob. Agents Chemother. 44 2000 1494 1498
18. S. Sundar, A.K. Goyal, D.K. More, M.K. Singh, and H.W. Murray Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultrashort courses of amphotericin-B lipid complex Ann. Trop. Med. Parasitol. 92 1998 755
19. S. Sundar, L.B. Gupta, M.K. Makharia, M.K. Singh, A. Vors, F. Rosenkaimer, J. Engel, and H.W. Murray Oral treatment of visceral leishmaniasis with miltefosine Ann. Trop. Med. Parasitol. 93 1999 589
20. C.P. Thakur Epidemiological, clinical and therapeutic features of Bihar - kala-azar (including post kala-azar dermal leishmanniasis) Trans. R. Soc. Trop. Med. Hyg. 78 1984 391
21. World Health Organization, 1996. Inf. Circ. WHO Mediterr. Zoon Control. Cent. 40, 11
22. World Health Organization, 1998. Tropical Diseases Research Progress 1997-1998. Fourteenth Programme Report - Leishmaniasis. pp. 1-22.
23. World Health Organization, 1999. TDR/WHO sponsored meeting on VL control, Varanasi, India. 12-14 (January).
24. World Health Organization, 2002. Special feature: miltefosine - breakthrough new oral treatment for visceral leishmaniasis, no. 68 (June issue)
25. J.H. Zar Biostatistical Analysis fourth ed. 1999 Prentice-Hall International Inc. USA